TENOFOVIR, LAMIVUDINE & DOLUTEGRAVIR (TLD)

A new HIV Treatment. One pill, once a day

TLD is recommended by the World Health Organization for first-line treatment of HIV. It can also be used in second-line treatment of HIV.

WHO QUALIFIES FOR TLD?

- All people living with HIV
- TB patients only after finishing their TB treatment.
- There are other ART options to consider while on treatment for TB.

Pregnant women and those planning for pregnancy should discuss the benefits and potential risks of TLD with their healthcare provider to make an informed choice.

TEE is recommended for women who want to get pregnant, and any other TEE patient who is happy with their treatment.

THE BENEFITS OF TLD ARE:

- To improve the lives of people living with HIV.
- To provide rapid viral suppression.
- High genetic barrier to resistance.
- Fewer side effects.
- Smaller tablet – easy to take.

TLD doesn’t replace condoms – use a condom consistently and correctly.

FOR MORE INFORMATION

- Visit your nearest healthcare provider/clinic
- Ask your healthcare provider
- www.health.gov.za
- www.bwisehealth.com
- National AIDS Helpline: 0800 012 322

TLD is manufactured and supplied by several pharmaceutical companies and comes in different colours, shapes and sizes – all contain the same ingredients. No one pill is better than the other.

Adcock Ingram  Aspen  Aurobindo  Cipla  Hetero  Macleods  Mylan  Sonke

www.health.gov.za  @HealthZA